Literature DB >> 22112472

Molecular cytogenetic evidence for multistep tumorigenesis: implications for risk assessment and early detection.

Subrata Sen1, Vicki Hopwood.   

Abstract

There is strong evidence that multistep tumorigenesis begins with the acquisition of somatic mutations which promote genomic instability. Genomic instability is an important malignant trait because genomic instability can generate the genetic diversity that is necessary for the transforming cell to acquire increasingly variable and aggressive tumor phenotypes. Genomic instability often manifests in the form of chromosomal instability (CIN) leading to the induction of aneuploidy, a phenomenon identified by high resolution molecular cytogenetic techniques. Fluorescent in situ hybridization (FISH) and Array Comparative Genomic Hybridization (aCGH) are two high resolution molecular cytogenetic techniques that allow detection of chromosomal aneuploidy and structural rearrangements occurring in pre-malignant and malignant lesions during tumor progression and invasion. These high resolution molecular cytogenetic techniques are used for genetic screening of single cells in pre-malignant and precursor malignant lesions as well as in exfoliated cells from body fluids and excreta. Consequently, molecular cytogenetic testing offers the promise of an extremely powerful method of risk assessment and early detection of cancer.

Entities:  

Mesh:

Year:  2010        PMID: 22112472     DOI: 10.3233/CBM-2011-0171

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  2 in total

1.  Hec1/Ndc80 is overexpressed in human gastric cancer and regulates cell growth.

Authors:  Ying Qu; Jianfang Li; Qu Cai; Bingya Liu
Journal:  J Gastroenterol       Date:  2013-04-17       Impact factor: 7.527

2.  Prognostic value of molecular markers and cytogenetic alterations that characterize breast cancer precursor lesions (Review).

Authors:  Maurizio DI Bonito; Monica Cantile; Rossella DE Cecio; Giuseppina Liguori; Gerardo Botti
Journal:  Oncol Lett       Date:  2013-09-17       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.